<DOC>
	<DOCNO>NCT00685750</DOCNO>
	<brief_summary>This study intend analyze expression specific set marker tumor sample serum patient Non-Small Cell lung Cancer ( NSCLC ) Stage III IV melanoma . The data obtain study use guide future development immunotherapy melanoma NSCLC patient . Moreover , analyse contribute definition marker potentially predictive clinical response specific anticancer therapy .</brief_summary>
	<brief_title>Expression Analysis Specific Markers Non-small Cell Lung Cancer Melanoma</brief_title>
	<detailed_description>This protocol post update due protocol amendment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>The patient ( male female ) least 18 year age . The investigator believe patient comply requirement protocol . The patient give his/her write informed consent take part study . The investigator believe possible obtain tumor tissue sample least 3 mm3 treatment require tumor tissue several week initiation treatment . The patient cancer one follow histological type , fulfil characteristic list respective cancer type : Cutaneous Melanoma , unresectable stage III stage IV • The patient histologically document unresectable stage III stage IV metastatic cutaneous melanoma . AND • The patient candidate one follow treatment : Firstline chemotherapy DTIC TMZ monotherapy [ group ME1 ] , Firstline chemotherapy agent DTIC/TMZ monotherapy combination ( may , need , include DTIC , TMZ , IL2 IFNγ ) [ group ME2 ] , Second higherline chemotherapy agent combination agent ( may , need , include DTIC , TMZ , IL2 IFNγ ; i.e. , systemic chemotherapy isolate limb perfusion consider secondline ) [ group ME3 ] , Palliative irradiation skin lesion ( ) /region , irrespective line treatment plan [ group ME4 ] , Topical palliative treatment imiquimod skin lesion ( ) , irrespective line treatment plan [ group ME5 ] . First high line treatment ipilimumab [ group ME6 ] . NSCLC , stage patient eligible neoadjuvant chemotherapy subsequent resection • The patient NSCLC stage ( defined International Staging System ) patient eligible neoadjuvant chemotherapy subsequent resection . AND • The patient candidate chemo ( radio ) therapy induction doublet neoadjuvant chemotherapy platinum plus second chemotherapy drug . [ Note : Induction radiotherapy permit . ] The recruitment patient NSCLC group end prematurely . The patient family history congenital hereditary immunodeficiency . The patient two week baseline receive following : Chemotherapeutic agent , Immunemodulating agent ( confine ) IFNα , IL2 , BCG anticancer therapeutic vaccine , Immunosuppressive agent corticosteroid [ except prednisone , equivalent , &lt; 0.5 mg/kg/day ( absolute maximum 40 mg/day , maximum duration treatment three week ) , inhaled topical steroid , allow ] . The patient currently receive anti cancer treatment another clinical trial . However , patient finish drug administration phase trial enter followup phase , patient include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>tumor antigen</keyword>
	<keyword>biomarkers</keyword>
</DOC>